Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
ACS Nano ; 15(12): 20127-20135, 2021 12 28.
Artículo en Inglés | MEDLINE | ID: mdl-34843225

RESUMEN

To harness the full potential of halide perovskite based optoelectronics, biological safety, compatibility with flexible/stretchable platforms, and operational stability must be guaranteed. Despite substantial efforts, none has come close to providing a solution that encompasses all of these requirements. To address these issues, we devise a multifunctional encapsulation scheme utilizing hydrogen bond-based self-recovering polymeric nanomaterials as an alternative for conventional glass-based encapsulation. We show that Pb in physically damaged halide perovskite solar cells can be completely contained within the self-recovering encapsulation upon submersion in a simulated rain bath, as indicated by in vitro cytotoxicity tests. In addition, self-recovering encapsulation accommodates stable device operation upon casual bending and even stretching, which is in stark contrast to conventional glass-based encapsulation schemes. We also demonstrate the concept of assembling user-defined scalable modular optoelectronics based on halide perovskite solar cells and light emitting diodes through the use of self-recovering conductive nanocomposites. Finally, long-term operational stability of over 1000 h was achieved under harsh accelerated conditions (50 °C/50% RH and 85 °C/0% RH) with the incorporation of an ultrathin atomic layer deposited TiO2 barrier underneath the multifunctional encapsulation. In light of these merits, the encapsulation scheme based on self-recovering polymeric nanomaterials is proposed as a simple, but practical solution to a multifaceted challenge in the field of halide perovskites.


Asunto(s)
Compuestos de Calcio , Nanoestructuras , Óxidos , Titanio
2.
Nanomaterials (Basel) ; 9(9)2019 Sep 16.
Artículo en Inglés | MEDLINE | ID: mdl-31527441

RESUMEN

An efficient hole-transporting layer (HTL) based on functionalized two-dimensional (2D) MoS2-poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS) composites has been developed for use in organic solar cells (OSCs). Few-layer, oleylamine-functionalized MoS2 (FMoS2) nanosheets were prepared via a simple and cost-effective solution-phase exfoliation method; then, they were blended into PEDOT:PSS, a conducting conjugated polymer, and the resulting hybrid film (PEDOT:PSS/FMoS2) was tested as an HTL for poly(3-hexylthiophene):[6,6]-phenyl-C61-butyric acid methyl ester (P3HT:PCBM) OSCs. The devices using this hybrid film HTL showed power conversion efficiencies up to 3.74%, which is 15.08% higher than that of the reference ones having PEDOT:PSS as HTL. Atomic force microscopy and contact angle measurements confirmed the compatibility of the PEDOT:PSS/FMoS2 surface for active layer deposition on it. The electrical impedance spectroscopy analysis revealed that their use minimized the charge-transfer resistance of the OSCs, consequently improving their performance compared with the reference cells. Thus, the proposed fabrication of such HTLs incorporating 2D nanomaterials could be further expanded as a universal protocol for various high-performance optoelectronic devices.

3.
Nanoscale ; 11(41): 19586-19594, 2019 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-31633140

RESUMEN

Designing an efficient and stable hole transport layer (HTL) material is one of the essential ways to improve the performance of organic-inorganic perovskite solar cells (PSCs). Herein, for the first time, an efficient model of a hole transport material (HTM) is demonstrated by optimized doping of a conjugated polymer TFB (poly[(9,9-dioctylfluorenyl-2,7-diyl)-co-(4,4'-(N-(4-sec-butylphenyl)diphenylamine)]) with a non-hygroscopic p-type dopant F4-TCNQ (2,3,5,6-tetrafluoro-7,7,8,8-tetracyanoquinodimethane) for high-efficiency PSCs. The PSC with the F4-TCNQ doped TFB exhibits the best power conversion efficiency (PCE) of 17.46%, which surpasses that of the reference devices, i.e., 16.64 (LiTFSI + TBP-doped Spiro-OMeTAD as the HTM) and 11.01% (LiTFSI + TBP-doped TFB as the HTM). F4-TCNQ doped TFB was believed to favor efficient charge and energy transfer between the perovskite and the hole transport layer and to reduce charge recombination as evidenced by steady-state photoluminescence (PL) and time-resolved photoluminescence (TRPL) analysis. Moreover, the hydrophobic nature of F4-TCNQ contributed to enhancing the stability of the device under ambient conditions with a RH of 45%. The device reported herein retained ca. 80% of its initial efficiency after 10 days, significantly superior to both LiTFSI + TBP-doped Spiro-OMeTAD (ca. 30%) and LiTFSI + TBP-doped TFB (ca. 10%) based counterparts. This simple yet novel strategy paves the way for demonstrating a promising route for a wide range of highly efficient solar cells and other photovoltaic applications.

4.
Rheumatol Int ; 27(11): 1071-7, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17404733

RESUMEN

Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (+/-12.1%) and LDL by 24% (+/-17%), compared with 1.8% (+/-7.5%) and 2.6% (+/-8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.


Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Hipercolesterolemia/complicaciones , Hipercolesterolemia/tratamiento farmacológico , Lupus Eritematoso Sistémico/complicaciones , Pravastatina/administración & dosificación , Adulto , Índice de Masa Corporal , LDL-Colesterol/sangre , LDL-Colesterol/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Femenino , Glucocorticoides/uso terapéutico , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/efectos adversos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Persona de Mediana Edad , Pravastatina/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA